Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00897806 · clinicaltrials.gov ↗
TERMINATED
Status
7
Enrollment
OTHER
Sponsor class

Stopped Terminated due to slow accrual.

Conditions

Interventions

Sponsor

M.D. Anderson Cancer Center

Collaborators